GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion in Pfizer ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Respiratory viruses can remain hidden in immune cells in the lungs long after the initial symptoms of an infection have ...

Illness from RSV is considered an infectious disease, usually leading to an infection of the upper respiratory tract but ...

Immunization appointments are now open for eligible Albertans. As of Monday (Oct. 7) both COVID-19 and influenza immunization ...

GSK: Some independent pharmacists said demand during the autumn vaccination season for respiratory syncytial virus shots has ...

The Netherlands will add the jab against the respiratory syncytial virus (RS virus) to the National Vaccination Program next ...

Infections caused by the latest variant have symptoms including fever, chills, fatigue, cough, congestion and headache.

Now that it’s autumn, many will be dodging illnesses like COVID, Influenza, Respiratory Syncytial Virus (RSV), and other ...